RJA
PRQR icon

Raymond James & Associates’s ProQR Therapeutics PRQR Stock Holding History

Raymond James & Associates’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,000
Closed -$76K – 4176
2021
Q1 		$76K Buy
+40,000
New +$204K ﹤0.01% 3812

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's PRQR Position: Q3 2023 in Review

Raymond James & Associates sold out of ProQR Therapeutics (PRQR) in Q3 2023, closing a stake of 20,550 shares — an estimated $33.3K sold.

Raymond James & Associates first reported a position in PRQR in Q1 2021 and held it in 5 quarters. The position peaked at $264K in Q1 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q3 2023.

  • Raymond James & Associates reported no remaining ProQR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 20,550 ProQR Therapeutics shares in Q3 2023, an estimated $33.3K.
  • Raymond James & Associates first reported a position in ProQR Therapeutics in Q1 2021 and held it in 5 quarters.
  • Raymond James & Associates's ProQR Therapeutics position peaked at $264K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.